Assessing the clinical benefits of lipid-disorder drugs

N Engl J Med. 2014 Jan 30;370(5):396-9. doi: 10.1056/NEJMp1313866.

Authors

William R Hiatt¹, Robert J Smith

Affiliation

¹ From the Division of Cardiology and CPC Clinical Research, Department of Medicine, University of Colorado School of Medicine, Aurora (W.R.H.); and the Alpert Medical School of Brown University and the Ocean State Research Institute, Providence Veterans Affairs Medical Center - both in Providence, RI (R.J.S.).

PMID: 24476429
DOI: 10.1056/NEJMp1313866

No abstract available

MeSH terms

Cholesterol / blood
Drug Approval*
Eicosapentaenoic Acid / adverse effects
Eicosapentaenoic Acid / analogs & derivatives*
Eicosapentaenoic Acid / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypercholesterolemia / blood
Hypercholesterolemia / drug therapy
Hypertriglyceridemia / blood
Hypertriglyceridemia / drug therapy*
Hypolipidemic Agents / adverse effects
Hypolipidemic Agents / therapeutic use*
United States
United States Food and Drug Administration

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
eicosapentaenoic acid ethyl ester
Cholesterol
Eicosapentaenoic Acid